Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

Published Date: 04 Jun 2025

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

4.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

5.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot